← Back to Search

Behavioral Intervention

Brief Enhanced Anxiety Sensitivity Treatment for Anxiety Disorders (BEAST Trial)

N/A
Recruiting
Led By Nicholas P Allan, PhD
Research Sponsored by VA Office of Research and Development
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Are English-speaking
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline to follow-up (measured six weeks after intervention session)
Awards & highlights

BEAST Trial Summary

This trial will test a treatment to reduce anxiety sensitivity and functional impairment in Veterans.

Who is the study for?
This trial is for English-speaking Veterans with high anxiety sensitivity and functional impairment, as indicated by specific scores on the SSASI and WHODAS 2.0 tests. It's not for those with severe schizophrenia, active psychosis or mania, immediate suicide risk, no smartphone access, or significant cognitive impairment.Check my eligibility
What is being tested?
The BEAST pilot study is evaluating a short-term treatment designed to lower anxiety sensitivity and improve daily functioning in Veterans. The focus is on how well participants accept this treatment and how practical it is to use.See study design
What are the potential side effects?
Since this trial involves a psychological therapy rather than medication, traditional side effects are not expected; however, some individuals may experience discomfort discussing their anxieties or temporary increases in anxiety.

BEAST Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I speak English.

BEAST Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline to follow-up (measured six weeks after intervention session)
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline to follow-up (measured six weeks after intervention session) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Mean change in Functional impairment
Mean change in anxiety sensitivity
Program satisfaction
Secondary outcome measures
Mean change in depression
Mean changes in anxiety
Mean changes in avoidance due to the COVID-19 pandemic
+2 more

BEAST Trial Design

1Treatment groups
Experimental Treatment
Group I: BEAST ConditionExperimental Treatment1 Intervention
A one-session intervention that can be delivered effectively by a clinician via telehealth and supplemented with a mobile app to provide opportunities to practice the skills learned in the face-to-face session.

Find a Location

Who is running the clinical trial?

VA Office of Research and DevelopmentLead Sponsor
1,606 Previous Clinical Trials
3,305,990 Total Patients Enrolled
1 Trials studying Anxiety Sensitivity
15 Patients Enrolled for Anxiety Sensitivity
Nicholas P Allan, PhDPrincipal InvestigatorVA Finger Lakes Healthcare System, Canandaigua, NY

Media Library

Brief Enhanced Anxiety Sensitivity Treatment (Behavioral Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05416203 — N/A
Anxiety Sensitivity Research Study Groups: BEAST Condition
Anxiety Sensitivity Clinical Trial 2023: Brief Enhanced Anxiety Sensitivity Treatment Highlights & Side Effects. Trial Name: NCT05416203 — N/A
Brief Enhanced Anxiety Sensitivity Treatment (Behavioral Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05416203 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the primary aim of this medical experiment?

"The primary aim of this research, which will be tracked from baseline to the end of virtual treatment (two weeks later), is patient satisfaction. Secondary objectives include evaluating mean changes in worry related to COVID-19 using the Coronavirus Impact Battery - Worry Scale (0-44 higher scores indicate worse outcomes); avoidance due to pandemic with the Coronavirus Impact Battery - Behavior Scales (0-48 higher scores denote a poorer result); and functional impairment caused by coronavirus via a modified WHODAS 2.0 scale measuring difficulties associated with COVID-19 complications (scores range from 0-28 where"

Answered by AI

Are there available openings for participants in the clinical trial?

"As per clinicaltrials.gov, this research endeavour is currently recruiting participants. The study was launched on September 1st 2022 and its details have been amended most recently on the 6th of that same month."

Answered by AI

What is the ceiling of enrollment for this clinical research project?

"Affirmative. According to clinicaltrials.gov, this research project is currently enrolling candidates. It was initiated on September 1st 2022 and the most recent update came on the 6th of that month. 15 participants are sought after at one medical facility."

Answered by AI
~1 spots leftby May 2024